Voyager Names Robin Swartz President; CEO Succession Set for Q1 2027
VYGR is trading near its 52-week low of $1.885 (14% above the low) on elevated volume (1.9× avg).
Summary
Voyager promoted Robin Swartz to President and set her to succeed CEO Alfred Sandrock after initial VY1706 Alzheimer's safety data in Q1 2027. The filing also details her $625,000 salary, 50% bonus target and promotion equity grants.
Key Events · Executive and Board Changes · VYGR
-
Swartz Appointed President
Robin Swartz, currently COO, CBO and principal financial officer, became President effective October 20, 2026.
-
CEO Succession Tied to VY1706 Data
Swartz is expected to succeed Alfred Sandrock as CEO after initial acute safety data from the VY1706 Alzheimer's trial in Q1 2027; Sandrock is expected to remain on the Board.
-
Compensation and Equity Grants
Base salary $625,000 with a 50% target bonus; effective November 1, 2026 she receives options on 318,500 shares and 68,250 RSUs under the 2025 Stock Incentive Plan.
-
Severance Terms
Qualifying termination pays 12 months of base salary plus a pro-rata bonus and up to 12 months of COBRA; a qualifying termination within 12 months after a sale event adds full acceleration of all equity awards.
Analysis · VYGR · Life Sciences
Voyager is lining up its next CEO. Robin Swartz, already COO, CBO and principal financial officer, becomes President immediately and is slated to take over from Alfred Sandrock after initial acute safety data from the VY1706 Alzheimer's trial lands in Q1 2027. Tying the handoff to that readout makes the data a de facto referendum on the transition, and Sandrock staying on the board keeps continuity. The promotion package — 318,500 options plus 68,250 RSUs granted November 1, 2026 — is standard for the role and small relative to the company's share base, so the news is about leadership continuity rather than dilution.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 29.1% of the 1524 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VYGR was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $134.9M. The 52-week trading range was $1.89 to $5.48. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.